Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress

Cancer Biology and Therapy

Volumn 5, Issue 7, 2006, Pages 745-748

  Fribley, Andrew ^a   Wang, Cun Yu ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Apoptosis; Cancer therapy; ER stress; Proteasome inhibitors

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BREFELDIN A; CISPLATIN; I KAPPA B ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PS 1145; THAPSIGARGIN; TUNICAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; DRUG INHIBITION; DRUG MECHANISM; ENDOPLASMIC RETICULUM; HUMAN; MULTIPLE MYELOMA; NONHUMAN; REVIEW; STRESS; TRANSCRIPTION INITIATION;

EID: 33751189389     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.7.2971     Document Type: Review

References (41)

1. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79:13-21.
2. Maniatis T. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 1999; 13:505-10.
3. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2003; 5:417-20.
4. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7:9-16.
5. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8:333-38.
6. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 1996; 274:784-87.
7. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-83.
8. Wang CY, Cusack J, Liu R, Baldwin AS. Control of inducible chemoresistance: Enhanced anti-tumor therapy via increased apoptosis through inhibition of NF-κB. Nature Med 1999; 5:412-17.
9. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-29.
10. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-76.
11. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26:119-29.
12. Sunwoo JB, Chen Z, Dong G, Yeh N, Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28.
13. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:1400-12.
14. Cusack Jr JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin Jr AS. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61:3535-40.
15. Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P, Cusack Jr JC. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Rad Onc Biol Phy 2001; 50:183-93.
16. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-47.
17. Bush KT, Goldberg AL, Nigam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. 1997; 272:9086-92.
18. Kawazoe Y, Nakai A, Tanabe M, Nagata K. Proteasome inhibition leads to the activation of all members of the heat-shock-factor family. Eur J Biochem 1998; 255:356-62.
19. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev 1999; 13:1211-33.
20. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002; 110:1383-8.
21. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24:9695-704.
22. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006; 281:11923-32.
23. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes nonsmall cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004; 128:740-48.
24. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL, Soengas MS. Chemical blockage of the proteasome inhibitory function of bortezomib: Impact on tumor cell death. J Biol Chem 2006; 281:1107-18.
25. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107:257-64.
26. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, (doi:10.1182/blood-2005-08-3531).
27. Nawrocki ST, Carew JS, Dunner Jr K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65:11510-19.
28. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100:9946-51.
29. Fribley A, Wang CY. Unpublished observation.
30. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL, Soengas MS. Chemical blockage of the proteasome inhibitory function of bortezomib: Impact on tumor cell death. J Biol Chem 2006; 281:1107-18.
31. Qin J, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJC, Rizzo P, Miele L, Nickoloff BJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65:6282-6293.
32. Gélinas C, White E. BH3-only proteins in control: Specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005; 19:1263-8.
33. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005; 4:443-9.
34. Li J, Lee B, Lee AS. Endoplasmic reticulum stress-induced apoptosis: Multiple pathways and activation of p53-upregulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006; 281:7260-70.
35. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5:18.
36. Landowski TH. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65:3828-36.
37. Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y, Imai K. Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res 2005; 111:5248-56.
38. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, Dalton WS, Beaupre DM. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006; 12:591-9.
39. Vij N, Fang S, Zeitlin PL. Selective inhibition of ERAD rescues uF508-CFTR and suppresses IL8 levels: Therapeutic implications. J Biol Chem 2006; doi:10.1074/jbc.M600509200.
40. Anderson KC. Bortezomib therapy for myeloma. Curr Hematol Rep 2004; 3:65.
41. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao T, Neuteboom STC, Richardson P, Palladino MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8:407-19.